Introduction
Hsp90 is an evolutionarily conserved molecular chaperone involved in the folding, stabilization, activation, and assembly of its 'client' proteins (1) (2) (3) . The growing list of Hsp90 client proteins include kinases, transcription factors, signaling molecules, and many other proteins involved in a wide range of biological processes under both normal and stress conditions (4) (5) (6) . Hsp90 is also engaged in the evolution and maintenance of disease states, such as cancer, by acting as a folding capacitor for unstable genetic variants, oncoproteins, or overexpressed proteins (7) (8) (9) . Although prokaryotes have one non-essential Hsp90 protein (HtpG), eukaryotes have multiple Hsp90 proteins including two cytosolic Hsp90 isoforms (Hsp90α and Hsp90β in mammals and Hsc82 and Hsp82 in yeast), and organelle-specific Hsp90 proteins such as endoplasmic reticulum Grp94 and mitochondrial TRAP1 found in higher eukaryotes, but not in yeast (10) (11) (12) . Accumulating evidence suggests that these Hsp90 proteins function by a common mechanism involving the cyclic conformational changes of the Hsp90 dimer (13) (14) (15) . The dimeric Hsp90 acts as a 'molecular clamp' in the form of a dynamic multichaperone complex in collaboration with various co-chaperones. Recent progress in the structural determination of Hsp90, either alone or in complexes with its co-chaperones, has provided information on how the conformational changes of Hsp90 are coupled to the ATP binding and hydrolysis, and how this ATPase cycle is regulated by the various co-chaperones (2, 15, 16) . This review focuses on the roles of various Hsp90 co-chaperones, which include the regulation of the Hsp90 ATPase cycle and selection of client proteins. The structural information of Hsp90 and its interaction with its co-chaperones can also provide insight into the design and development of noble Hsp90 inhibitors for use as anti-cancer drugs.
Molecular mechanism of the Hsp90 chaperone machinery
The conserved structure of Hsp90 consists of the N-terminal ATP-binding domain, the middle domain containing the amphipathic loop implicated in client protein-binding, and the C-terminal dimerization domain (1, 15) . With the exception of HtpG and TRAP1, the N-terminal and middle domains are connected by a charged disordered linker, and the C-terminal extreme end has an MEEVD motif which is a binding site for the tetratricopeptide repeat (TPR) domains found in several co-chaperones (17, 18) . While the C-terminal domain provides for the constitutive dimerization of Hsp90, the N-terminal domain undergoes transient dimerization driven by ATP binding (19, 20) . A recent kinetic model based on the real-time detection of the conformational changes of Hsp90 by fluorescence resonance energy transfer (FRET) proposed five intermediate states which might represent the various stages of the Hsp90 cycle suggested from previous structural and biochemical studies (21) (Fig. 1) . The binding of ATP to the 'open' Hsp90 dimer leads to the approximately 120 o rotation of the 'lid' segment (residues 94-125 in yeast Hsp90), which causes it http://bmbreports.org (26, 30) . In contrast, Aha1 stimulates the ATPase cycle by binding to the middle domain of Hsp90 and triggering the rearrangement of the catalytic loop containing R380 (shown in blue) to an active conformation (49) . P23/Sba1 binds to the closed conformation of the Hsp90 dimer, arresting the ATPase cycle. The molecular surface of yeast Hsp90 dimer complexed with Sba1 is also presented (16) .
to flap over the mouth of the ATP binding pocket (I1) (2, 16) . In addition, this lid closure triggers the strand swapping of the most N-terminal β-strand of each monomer, resulting in the close association of the N-terminal domains (I2). The dimerization of the N-terminal domains is followed by further conformational changes, leading to a closed conformation with a compact twisted structure (16, 22) . In the closed state, the middle domain catalytic loop interacts with the closed lid segment, which allows the interaction of the active site, Arg380, with the γ-phosphate group of the ATP, leading to the polarization of the β-γ phosphodiester bond for hydrolysis (16) . (23), suggesting that the opening and closing of the Hsp90 molecular clamp is closely related to the folding or activation of its client proteins. However, it is still largely unknown as to how these conformational changes are coupled to the folding of a wide range of structurally unrelated client proteins. http://bmbreports.org BMB reports
Co-chaperones working as adaptor proteins for client proteins
The activity of Hsp90 is regulated by the dynamic association of various co-chaperones. More than a dozen co-chaperones have been identified so far which can regulate Hsp90 activity in diverse ways, such as by the recruitment of client proteins and the regulation of the ATPase cycle (14, 15) . Cdc37 and Sgt1 serve as adaptor proteins to recruit a specific set of client proteins to Hsp90 by binding to the open conformation of Hsp90. Cdc37 is mainly involved in recruiting various kinds of protein kinase client proteins to Hsp90 (25) . The N-terminal domain of Cdc37 binds to the kinase, while its C-terminal domain interacts with the open conformation of the lid segment of Hsp90, inhibiting its N-terminal dimerization (26) (Fig. 2) . Therefore, Cdc37 can arrest the Hsp90 ATPase cycle, which might contribute to the loading process of the client proteins.
Sgt1 consists of the TPR, CS (CHORD-containing proteins and Sgt1), and SGS (Sgt1-specific) domains (27) . Even in the presence of the TPR domain, Sgt1 interacts with Hsp90 through the CS domain instead of the TPR domain (28) (29) (30) . The recent crystal structure determination of the plant Hsp90-Sgt1 interaction revealed the binding of the Sgt1 CS domain to the N-terminal domain of Hsp90, including the most N-terminal strand region involved in stand swapping during N-terminal dimerization (30) (Fig. 2) . In addition, a structural model suggests that a steric clash of the two CS domains occurs when they bind simultaneously to the closed form of Hsp90 (30) . Therefore, like Cdc37, Sgt1 might hinder the progress of the ATPase cycle. Sgt1 functions as an adaptor linking various target proteins to Hsp90 (27) . The TPR domain of Sgt1 interacts with Skp1 in the context of the CBF3 kinetochore complex or SCF E3 ubiquitin ligase (31, 32) . In addition, through its SGS domain, Sgt1 can interact with many LRR (leucine rich repeat) -containing proteins, such as yeast adenylate cyclase Cdc35 (33), plant R proteins (27, 34) and mammalian NLR (Nod-like receptor) proteins including Nod1 and Nalp3 (35) (36) (37) . Especially, R and NLR proteins are homologous proteins involved in disease resistance in plant and innate immunity in mammals, respectively (38) (39) (40) . Both R and NLR proteins have been identified as Hsp90 client proteins, and Sgt1 seems to be responsible for their recruitment to Hsp90. Moreover, plant RAR1 protein is another Hsp90 co-chaperone required for the activation of a subset of R proteins (41, 42) . RAR1 contains two CHORDs (Cys and His rich domains) which are involved in the interaction with the Hsp90 N-terminal domain (CHORD I) and with the CS domain of Sgt1 (CHROD II) (34) . It has been shown that the CS domain of Sgt1 can interact with Hsp90 and RAR1 through the opposite interface, allowing the formation of a ternary complex (43) . RAR1 might contribute to enhancing the Hsp90-Sgt1 chaperone machinery through such a dynamic and complex interaction (43) . Mammals have two RAR1 homologues, Chp-1 and melusin, which have an additional CS domain at the C-terminus (44) . While it has been shown that muscle-specific melusin protein is involved in stress adaptation to mechanical stimuli in the heart, the biological function of Chp-1 has not yet been identified (45) . However, like RAR1, both Chp-1 and melusin seem to act as Hsp90 co-chaperones. The CHORD II of Chp-1 interacts with Hsp90, while CHORD I interacts with another co-chaperone, PP5 (35, 46) . Also, melusin has been shown to interact with Hsp90 and Sgt1 (47). It is not yet clear whether Chp-1 shares functional similarity with RAR1 by regulating NLR activation and innate immunity. At least, overexpressed Chp-1 was found in a Nod1-Hsp90 complex, although not in an endogenous complex (35, 36) .
Co-chaperones regulating Hsp90 ATPase cycle
While the binding of Cdc37 or Sgt1 to the open conformation of Hsp90 can slow down the progression of N-terminal dimerization, the co-chaperone, p23/Sba1, binds to the ATP-bound closed conformation of Hsp90, inhibiting further conformational changes (16) (Fig. 2) . The binding sites of p23/Sba1 include the two N-terminal domains of the closed dimer and one middle domain of a monomer. Although p23/Sba1 has structural similarity to the CS domain of Sgt1, p23/Sba1 binds to Hsp90 through its C-terminal domain, which is absent in Sgt1 (16, 28) .
Aha1, on the other hand, activates the Hsp90 ATPase cycle (48, 49) . The N-terminal domain of Aha1 binds to the middle domain of Hsp90, leading to the rearrangement of the catalytic loop and causing it to come into contact with the ATP in the N-terminal pocket (49) (Fig. 2) . A recent report based on real-time FRET analysis showed that Aha1 could facilitate the transition from the closed to open conformation, even in the absence of a binding nucleotide (21) .
TPR-containing co-chaperones
The majority of the co-chaperones identified so far contain the TPR domain which can bind to the C-terminal end of Hsp90 (14, 17) . The TPR-containing co-chaperones, including Hop/Sti1, immunophilins (FKBP51, FKBP52, and Cyp40), PP5/Ppt1, and CHIP have specific functional domains involved in the regulation of Hsp90 client proteins or the Hsp90 chaperone machinery itself.
Hop/Sti1 has two TPR domains which allow for its simultaneous binding to Hsp70 and Hsp90, mediating the transfer of the client protein from Hsp70 to Hsp90 (50) . Hop/Sti1 also inhibits Hsp90 ATPase activity by an as yet unknown mechanism, which is thought to be advantageous for the loading of the client protein to the Hsp90 chaperone machinery (51) .
Immunophilins harboring the peptidyl proryl isomerase (PPIase) domain exert differential effects on the regulation of steroid receptors (SR) (52) . Even with around 70% similarity between FKBP1 and FKBP2, FKBP1 inhibits the glucocorticoid http://bmbreports.org receptor (GR) activity (53) , while FKBP2 potentiates the GR, as well as the androgen receptor (AR) (54) and progesterone receptor (PR) (55) . It has been shown that the PPIase activity of FKBP2 is not necessary for the activation of GR (56) . In addition, the PPIase domain of FKBP52 has been proposed as an adaptor linking GR-Hsp90 complex to the motor protein dynein for the movement of the GR complex to the nucleus along the microtubules (57) . Therefore, the role of PPIase activity in the function of immunophilin co-chaperones still remains to be clarified.
On the other hand, PP5/Ppt1 has phosphatase activity which is under the control of the autoinhibition by the intramolecular interaction between the phosphatase domain and N-terminal TPR domain (58) . This autoinhibition can be relieved by TPR-binding proteins such as Hsp90 or by a certain form of fatty acid ligands (59) . It has been shown that yeast Ppt1 is involved in the activation of Hsp90 through direct dephosphorylation (60) . Recently, PP5 has also been shown to dephosphorylate Cdc37, leading to the release of Cdc37 from Hsp90 (61). Therefore, PP5 seems to regulate the dynamic assembly of the Hsp90 machinery during the folding of kinase client proteins recruited by Cdc37. Finally, even though PP5 has been implicated in a wide range of cellular functions, some of the known substrates of PP5, including the glucocorticoid receptor (GR), Tau, and Raf, are also Hsp90 client proteins (62) (63) (64) , implying that at least a subset of PP5 substrates can be recognized by PP5 in the context of the Hsp90 chaperone complex. Therefore, any components assembled in an Hsp90 chaperone complex might be able to serve as substrates for PP5/Ppt1.
CHIP is another TPR-containing co-chaperone having E3 ubiquitin ligase activity (65) . It has been suggested that CHIP might be involved in the ubiquitin-mediated degradation of Hsp90 client proteins which failed to fold properly. However, this hypothesis is weakened by the slight degree of overlap between Hsp90 and CHIP substrates (2) . There are other TPRcontaining co-chaperones which seem to have rather specific functions; Unc45 in the assembly of myosin filaments (66), Tom70 in mitochondrial protein import (67) , and yeast Tah1 in the assembly and maintenance of snoRNP (68, 69) .
Development of Hsp90 inhibitors
In relation to its role as a folding capacitor, Hsp90 has been shown to be implicated in many pathological conditions such ischemia and reperfusion, infections, neurodegenerative diseases, and cancer (9, 70, 71) . Recently, Hsp90 has received much attention as a promising target for anti-cancer drug development. The client proteins of Hsp90 include many oncogenic proteins such as Her2/ErbB2, Akt, Raf-1, Hif-1α, hormone receptors, survivin, mutant p53, and hTERT (72) (73) (74) . The inhibition of Hsp90 leads to the simultaneous degradation of these oncogenic client proteins by a ubiquitin-dependent proteasome pathway (72, 75, 76) . Therefore, Hsp90 inhibitors have the potential to act as multi-pronged effectors toward many cancer targets. Furthermore, it has been shown that Hsp90 derived from tumor cells has higher activity and ATP binding affinity than the latent form in normal cells, allowing for the specific targeting of Hsp90 inhibitors toward tumor cells, while having little effect on normal cells (77) . In addition, even the cell-impermeable Hsp90 inhibitor which can target cell surface Hsp90 has been shown to be effective in the inhibition of tumor cell migration and invasion (78) .
The majority of Hsp90 inhibitors developed so far dock to the N-terminal ATP binding pocket of Hsp90 and block the ATPase cycle which is essential for the Hsp90 function (79, 80) . This class of Hsp90 inhibitors includes the natural products, geldanamycin (GA) and radicicol. More recently, the less toxic and more effective GA derivatives, 17-allylamino-17-demethoxygeldanamycin (17-AAG) (81) and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) (82), have been developed. Purine-scaffold derivatives such as PU3, PU24FCl, and PU-H58 were developed based on the structure of the nucleotide ligand (83, 84) . Novel scaffolds for Hsp90 inhibitors have been further developed by either high throughput screening or the structure-based virtual screening of a chemical library. Diarylpyrazole was initially identified by high throughput screening and its more potent derivatives, pyrazole amide and isoxazole, have since been developed (85, 86) . 17-AAG initially showed promising outcomes in several clinical Phase I and Phase II trials in cancer, and some of the newly developed Hsp90 inhibitors have also entered clinical trials (86) . On the other hand, the structural information of the ATP binding to the Hsp90 N-terminal domain was successfully used for the virtual screening of Hsp90 inhibitors docking to the ATP binding pocket. Using such a strategy, new scaffolds, such as 1-(2-phenol)-2-naphthol (87) and 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) (88), were identified. We also used a newly developed structure-based virtual screening tool with an accurate solvation model for putative ligands to identify novel classes of Hsp90 inhibitors having scaffolds such as 3-phenyl-2-styryl-3H-quinazolin-4-one and pyrimidine-2,4,6-trione (89, 90) . This virtual screening tool might also be useful to design and screen more specific Hsp90 inhibitors which can block Hsp90 interactions with specific co-chaperones or client proteins.
Conclusions and perspectives
The ever expanding list of client proteins and biological processes regulated by Hsp90 makes it clear that the Hsp90 chaperone machinery plays a central role by acting as a molecular folding capacitor and hub for molecular assembly, coordinating the dynamic networks of intracellular and even extracellular proteins. Recent progress in elucidating the structure to function relationship of Hsp90 has given us a better idea of how this molecular machinery works. However, our ability to understand this exciting molecular machinery is still at an early http://bmbreports.org BMB reports stage. It is still completely unknown as to how Hsp90 recognizes and stabilizes or activates a wide range of structurally unrelated proteins. Also, another challenge is to elucidate the biological role of each co-chaperone and the regulatory mechanism for the selective and dynamic association and dissociation of a set of co-chaperones depending on the client proteins. We might also need to understand other modifications of Hsp90, such as its phosphorylation and acetylation, which seem to be a part of the regulatory process. The initial success in targeting Hsp90 for cancer treatment has led to the expectation that Hsp90 might also serve as a potential therapeutic target for other diseases involving Hsp90, such as neurodegenerative or inflammatory diseases. A detailed understanding of this complex chaperone machinery at both the systematic and atomic level might be required to answer these open questions and to develop disease-specific drugs targeting Hsp90.
